About Reactive Oxygen®
Reactive Oxygen® technology allows for the accurate delivery of low levels of hydrogen peroxide – a reactive oxygen species – at a controlled antimicrobial potency to the infection site for a sustained period.
Reactive Oxygen® technology is now rapidly being developed to treat Complex Poloymicrobial Skin Lesions (CPSL), reducing the need for using traditional antibiotics.
While traditional antimicrobials are increasingly subject to antimicrobial resistance, Reactive Oxygen® has been demonstrated to destroy a broad range of bacteria, including MRSA, Pseudomonas aeruginosa and E. Coli, which have developed resistance to traditional antibiotic drugs. It is also effective against colonies of bacteria, or biofilms, that make infections difficult to treat with traditional antibiotics.
The mission of Matoke Holdings Ltd.™ is to develop a new solution to tackle antimicrobial resistance.
The efficacy of Reactive Oxygen® technology to date is supported by a weight of academic research, with further publications due. Our research papers are available on request at firstname.lastname@example.org.